Replies to post #129527 on Biotech Values

[DewDiligence]

INCY has argued precisely the opposite (given they have a JAK1/2 drug). But I assume they are talking their book.

[jq1234]

Of course INCY has argued precisely the opposite

Hmm...Maybe because theirs don't inhibit JAK3. PFE originally thought Tofacitinib was JAK3. Then it was corrected Tofacitinib is actually pan-JAK.